Hide Board Information

Show Board Information

Autolus Therapeutics plc AUTL

Board Mod: Add me as mod

Asst Mods:

Last Post: 03/07/2023 5:46:59 AM

Board Marks: 0

Posts Today: 0

Board Views Today: 1

Autolus Therapeutics plc (NASDAQ: AUTL) Stock Message Board

1. AUTL Company Profile

    

2. AUTL Time & Sales

    

3. AUTL Recent News

    

4. AUTL Filings

    

5. AUTL Financials

    

6. AUTL Buy Rating

Create New Post View All Posts Board Mark Banned

Post

Subject

Author

Posted On

2	is no one intersted in this	rusi	03/07/2023 5:46:59 AM
1	AUTL 25% v41,5M c6.97 f72,9M	znewcar1	11/08/2021 4:22:57 PM

Recent Articles

• Investor Class Action Filed Against Geron Corporation's Leadership
• Growth Prospects of Assembly Line Solutions Through 2032
• Badge Inc. Celebrates Five Distinguished Global InfoSec Awards
• Class Action Lawsuit Filed Against Sana Biotechnology, Inc.
• Southwest Airlines Unveils New Fare Structures and Benefits
• Transforming Life After Sports: A New Path for Athletes
• Luxury Travel and Sustainability: A Growing Partnership
• Pomerantz Law Firm Initiates Class Action Against SoundHound AI
• Transforming Healthcare with AI: A Collaborative Future Ahead
• Transforming Money for the Digital Age with Lightspark
• Insights on Recent Managers' Transactions at Nokia Corporation
• Insights on Recent Managerial Transactions at Nokia Corporation
• West Red Lake Gold Honors Workers on National Day of Mourning
• Myosin Therapeutics Secures Funding for Groundbreaking Clinical Study
• Sabre Corporation to Host Earnings Webcast for Q1 2025
• Quantum Computing Inc. Faces Class Action Lawsuit Dynamics
• California Casualty Achieves Exceptional Financial Stability Rating
• Empowering Workplace Wellness Through Global Institute Initiative
• Honeywell Declares Strong Quarterly Dividend for Shareholders
• CS Genetics Welcomes Paul McEwan as New Board Director
• Class Action Filed Against e.l.f. Beauty Over Inventory Issues
• Opportunities for Skyworks Solutions Investors Amid Lawsuit
• Immunotherapy Breakthrough: A New Era in Cancer Treatment
• METLEN Capital Markets Day: Paving the Way for Future Growth
• Jennifer Smeltzer Recognized Among Top Real Estate Agents
• Max Roix Elevates to Advisor at Viking Mergers & Acquisitions
• Nanette Wilcox Takes Leadership at BayCare Hospital Wesley Chapel
• Vessi Welcomes Lorrin Pascoe as New CMO for Brand Expansion
• Unlocking the Secrets of Cloud Mining with Rich Miner
• Banijay Group Shares: Key Transactions That Matter
• Relmada Therapeutics Showcases Breakthrough Phase 2 Findings
• Hoag Welcomes Notable Oncologist to Enhance Cancer Care Efforts
• Volta Labs Launches Initiative to Aid Academic Research Efforts
• Sapiens Expands Insurance Solutions with Acquisition of AdvantageGo
• Greg Kiger Appointed as COO to Drive Community Development
• METLEN Reveals Future Plans to Expand Towards €2 Billion EBITDA
• Transforming Training: Yardi Aspire's Innovative AI Tools
• Celebrating Dr. Willeam A. Choby's Acclaim in Dentistry
• Investor Opportunities in Sana Biotechnology's Legal Landscape
• Insights on IBA's Recent Share Buyback Initiative and Its Impact
• Recordati's Ambitious 2025-2027 Growth Strategy Unveiled
• Vibrant Growth in Adaptogens Market Aims for $19.88 Billion
• Engaging Pet Nutrition Webinars for Veterinary Experts in 2025
• PG&E Unveils New Service to Enhance Electric Vehicle Connections
• Aurora Pharmaceutical Supports Customers by Freezing Prices
• Susan Lucci's La Lucci: A Memoir Full of Heart and Spirit
• Health Monitor Network Achieves 12 Hermes Creative Awards
• Prominent Speakers to Inspire High Point University Graduates
• Virbac Releases 2024 Annual Report Highlighting Key Insights
• Seth Grae Discusses Nuclear Energy's Vital Future on Schwab Live